# A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

> **NCT01785771** · PHASE3 · TERMINATED · sponsor: **Intarcia Therapeutics** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ITCA 650 (exenatide in DUROS)

## Key facts

- **NCT ID:** NCT01785771
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Decision by Sponsor
- **Last updated:** 2019-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785771, "A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01785771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*